Tango Therapeutics raises ~$212M via registered direct offering and PIPE

Tango Therapeutics, Inc.

Registered direct offering of 21.0M shares and 3.2M pre-funded warrants at $8.66; net proceeds ~$197M.
Separate PIPE of 1.7M shares at $8.66 for ~$15M total gross proceeds.
Proceeds to advance pipeline and general corporate purposes; cash runway extended into 2028.
Closings expected October 24, 2025; customary conditions apply.
Officers and directors to enter 60-day lock-up agreements per PIPE terms.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Tango Therapeutics, Inc. issued 1,732,101 shares of common stock to a certain accredited investor for $8.66 per share.

Security: common stock
Shares: 1,732,101 shares
Purchaser: a certain accredited investor
Consideration: $8.66 per share

Exact text from the filing

the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with a certain accredited investor (the “Purchaser”), for the private investment in public equity (the “Private Placement”) of 1,732,101 shares (the “PIPE Shares”) of the Company’s Common Stock, at a purchase price of $8.66 per share.

View on SEC.gov

Browse all equity issuances →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-249302

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.